

Supplement: Safety of Anti-Osteoarthritis Medications

Safety of topical non-steroidal anti-inflammatory drugs in osteoarthritis: Outcomes of a systematic review and meta-analysis

Germain Honvo, Victoria Leclercq, Anton Geerinck, Thierry Thomas, Nicola Veronese, Alexia Charles, Véronique Rabenda, Charlotte Beaudart, Cyrus Cooper, Jean-Yves Reginster, Olivier Bruyère

ELECTRONIC SUPPLEMENTARY MATERIAL 4

1. Subgroup analyses of “Any adverse event” (total adverse events) with topical diclofenac versus placebo in patients with osteoarthritis (OA)

Figure 64: Meta-analysis of “Any Adverse event” with topical diclofenac versus placebo in patients with OA, by OA location




Figure 65: Meta-analysis of “Any Adverse event” with topical diclofenac versus placebo in patients with OA, by topical formulation (Gel, Cream, etc.)




Figure 66: Meta-analysis of “Any Adverse event” with topical diclofenac versus placebo in patients with OA, by daily dose (mg)





Figure 67: Meta-analysis of “Any Adverse event” with topical diclofenac versus placebo in patients with OA, by study duration (in weeks)



2. Subgroup analyses of “Withdrawal due to adverse events” with topical diclofenac versus placebo in patients with OA

Figure 68: Meta-analysis of “Withdrawal due to adverse events” with topical diclofenac versus placebo in patients with OA, by OA location




Figure 69: Meta-analysis of “Withdrawal due to adverse events” with topical diclofenac versus placebo in patients with OA, by topical formulation (Gel, Cream, etc.)




Figure 70: Meta-analysis of “Withdrawal due to adverse events” with topical diclofenac versus placebo in patients with OA, by daily dose (mg)




Figure 71: Meta-analysis of “Withdrawal due to adverse events” with topical diclofenac versus placebo in patients with OA, by study duration (in weeks)

